Simpson, Colin RKerr, StevenKatikireddi, Srinivasa VittalMcCowan, ColinRitchie, Lewis DPan, JiafengStock, Sarah JRudan, IgorTsang, Ruby S Mde Lusignan, SimonHobbs, F D RichardAkbari, AshleyLyons, Ronan ARobertson, ChrisSheikh, Aziz2022-11-212022-11-212022-08-15Simpson, C R, Kerr, S, Katikireddi, S V, McCowan, C, Ritchie, L D, Pan, J, Stock, S J, Rudan, I, Tsang, R S M, de Lusignan, S, Hobbs, F D R, Akbari, A, Lyons, R A, Robertson, C & Sheikh, A 2022, 'Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland', Nature Communications, vol. 13, 4800. https://doi.org/10.1038/s41467-022-32264-62041-1723PubMedCentral: PMC9377297https://hdl.handle.net/2164/19574Acknowledgements EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care. FDRH acknowledges part support as Director of the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, and Theme Lead of the NIHR OUH BRC. We thank Dave Kelly from Albasoft Ltd for his support with making primary care data available and Frances Burns, Mathhew Thankur, Wendy Inglis-Humphrey, Vicky Hammersley, Dom Balharry and Laura Brook, Morag Edwards and Laura Gonzalez Rienda for their support with project management and administration. We thank the EAVE II Public Advisory Group. Our thanks to Prof. Jenni Quint, Prof. Rustam Al-Shahi Salman and Dr. Quentin Hill for their help with reviewing code lists.7772390engSDG 3 - Good Health and Well-beingAdultBNT162 VaccineCOVID-19/epidemiologyCOVID-19 Vaccines/adverse effectsHumansProspective StudiesPurpura, Thrombocytopenic, Idiopathic/epidemiologyScotlandThromboembolism/epidemiologyVaccination/adverse effectsR Medicine (General)Medical Research Council (MRC)MR/R008345/1OtherMC_PC_19004UK Research and Innovation (UKRI)MC_PC_20058National Institute for Health Research (NIHR)ARCR1Journal article10.1038/s41467-022-32264-613